| __timestamp | Iovance Biotherapeutics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 2613100000 |
| Thursday, January 1, 2015 | 999000 | 2891500000 |
| Friday, January 1, 2016 | 978000 | 3228800000 |
| Sunday, January 1, 2017 | 952000 | 2966700000 |
| Monday, January 1, 2018 | 956000 | 2900200000 |
| Tuesday, January 1, 2019 | 8122999 | 3064100000 |
| Wednesday, January 1, 2020 | 8712000 | 3248100000 |
| Friday, January 1, 2021 | 13980000 | 2722500000 |
| Saturday, January 1, 2022 | 21135000 | 2996200000 |
| Sunday, January 1, 2023 | 10755000 | 2975200000 |
Unleashing insights
In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost structures is crucial. Perrigo Company plc, a stalwart in the pharmaceutical industry, consistently reported a cost of revenue averaging around $2.96 billion annually from 2014 to 2023. This stability reflects its robust market presence and operational efficiency. In contrast, Iovance Biotherapeutics, Inc., a rising star in biotechnology, exhibited a more dynamic cost pattern. Starting with a modest $952,000 in 2017, Iovance's cost of revenue surged by over 2,000% to approximately $21 million by 2022. This dramatic increase underscores its aggressive growth strategy and investment in innovative therapies. The juxtaposition of these two companies highlights the diverse financial strategies within the industry, offering valuable insights for investors and stakeholders alike.
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Perrigo Company plc
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: BeiGene, Ltd. vs Perrigo Company plc
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Perrigo Company plc
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Perrigo Company plc
Analyzing Cost of Revenue: Walgreens Boots Alliance, Inc. and Perrigo Company plc
Lantheus Holdings, Inc. vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Alkermes plc and Perrigo Company plc's Expenses
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Wave Life Sciences Ltd.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.